Pune on Monday reported nine suspected cases of Guillain-Barre Syndrome (GBS), an immunological nerve disorder, taking the tally in Maharashtra`s second largest city to 110, officials said, reported ...

Guillain-Barre Syndrome (GBS) is a serious illness that often progresses rapidly, making the patient bedridden in a few days ...

The health officials said that a new Guillain-Barre Syndrome case was reported in Pune on Tuesday; number of suspected GBS ...

Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said. Dr.

Maharashtra CM reviews GBS cases, instructs officials for treatment arrangements, and coverage under MJPJAY in government ...

When you think about infectionsclassically the thought runs to malariawith recent cases also in Italy, tuberculosis or HIV ...

Pune reported nine suspected new cases of Guillain-Barre Syndrome (GBS), raising the city's total to 110 cases. Health officials have noted gender distribution, ventilator usage, and are conducting ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...